Mission Statement, Vision, & Core Values (2026) of Jinyu Bio-technology Co., Ltd.

From its founding in 1993 Jinyu Bio-Technology Co., Ltd. has grown into a prominent Chinese biotech firm that blends agricultural impact with global reach, reporting approximately ¥2.5 billion in revenue in 2022 after a 15% year‑over‑year increase and claiming roughly 10% market share in China's microbial fertilizer segment, operating production lines capable of producing 200 million doses of vaccines and 50,000 tons of probiotics annually while exporting to over 30 countries (with exports contributing about 40% of 2022 revenue), investing roughly ¥200 million in collaborative R&D that supports sustainability goals including a 20% reduction in carbon emissions over three years and targets such as a 30% carbon footprint cut and 95% customer satisfaction by 2025-read on to explore how Jinyu's mission, vision, and core values translate these concrete numbers into strategic action.

Jinyu Bio-technology Co., Ltd. (600201.SS) - Intro

• Product portfolio: probiotics, vaccines, feed additives, diagnostic kits.
• Production capacity: ~200 million vaccine doses/year; ~50,000 tonnes probiotics/year.
• Market footprint: ~10% share of China's microbial fertilizer market (2022).
• International reach: exports to 30+ countries; ~40% of 2022 revenue from Southeast Asia, Europe, North America.

• R&D focus: microbial technologies, vaccine innovation, diagnostic accuracy.
• Quality assurance: GMP-compliant facilities and industry-standard production controls.
• Farmer impact: increase yield and disease resistance while lowering chemical fertilizer and antibiotic dependence.

• Scientific Rigor - Evidence-based product development and peer-reviewed validation.
• Sustainability - Reduction of chemical footprints and promotion of circular agricultural practices.
• Quality & Compliance - Strict adherence to regulatory standards and continuous improvement.
• Customer Centricity - Practical solutions tailored to producer needs and on-farm realities.
• Global Responsibility - Ethical export practices and technology transfer to emerging markets.

• Scale R&D spend toward next-gen microbial consortia and thermostable vaccines to capture additional market share.
• Expand capacity utilization and add high-efficiency lines to increase annual vaccine throughput beyond 200 million doses.
• Strengthen distribution and regulatory registration in target export markets to sustain and grow the ~40% export revenue contribution.
• Invest in sustainability initiatives (waste reduction, energy efficiency) across production sites to align with environmental commitments.

Jinyu Bio-technology Co., Ltd. (600201.SS) - Overview

Jinyu Bio-technology Co., Ltd. (600201.SS) positions itself as a biotechnology leader focused on improving soil health and raising crop yields through sustainable, science-driven agricultural inputs. The company blends commercial deployment with targeted R&D investments and measurable environmental commitments to align with global sustainability and climate goals.

• Primary markets: soil conditioners, biofertilizers, biostimulants, and microbial-based crop protection for row crops and specialty agriculture.
• Listing: Shanghai Stock Exchange (600201.SS).
• 2022 strategic R&D collaboration funding: approximately ¥200,000,000 allocated to joint projects with agricultural research institutes.
• Environmental performance: reported 20% reduction in carbon emissions over the past three years.

Mission Statement

• Deliver high-quality biotechnology solutions that measurably improve soil health and crop yield across diverse agro-ecosystems.
• Promote sustainable agricultural practices that conserve natural resources and mitigate climate impact.
• Invest in research and development to drive continual innovation and respond to evolving market and regulatory needs.
• Enhance customer satisfaction via superior technical support, product reliability, and long-term partnerships with farmers, distributors, and research institutions.

Vision

To be a global benchmark in sustainable agricultural biotechnology - creating resilient agroecosystems, empowering farmers with science-based tools, and contributing to a low-carbon food system.

Core Values

• Scientific Rigor: Evidence-based product development and field validation.
• Sustainability: Measurable reductions in environmental footprint and promotion of regenerative practices.
• Customer Centricity: Long-term partnerships, technical service, and farmer-focused solutions.
• Collaboration: Open innovation with research institutes, universities, and industry partners.
• Integrity: Transparent reporting, compliance, and responsible governance.

Key Metrics & Strategic Commitments

For a deeper corporate background and context on mission and ownership, see: Jinyu Bio-technology Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Jinyu Bio-technology Co., Ltd. (600201.SS) - Mission Statement

• Advance human and animal health through novel biologics, vaccines, and diagnostic platforms.
• Enhance agricultural resilience with biotech-enabled crop protection and yield-enhancement solutions.
• Integrate green manufacturing and resource-efficient processes across the value chain.
• Deliver superior customer experiences and measurable outcomes for partners and end-users.
• Scale internationally, establishing research hubs and commercial presence in Europe and North America.

• Carbon footprint reduction: reduce greenhouse gas emissions by 30% (baseline year) by the end of 2025 through energy efficiency, renewable energy procurement, and process optimization.
• Customer satisfaction: raise overall customer satisfaction ratings to 95% by 31 December 2025 by expanding after-sales support, improving product reliability, and implementing regular NPS/CSAT tracking.
• Global R&D footprint: establish dedicated research & development centers in Europe and North America by 2026 to accelerate regulatory harmonization and local collaboration.
• Workforce development: increase training hours and professional development investment per employee to strengthen talent, productivity, and retention.

• Scientific Rigor - decisions guided by evidence, reproducibility, and regulatory compliance.
• Customer Centricity - product design and service models focused on measurable client outcomes.
• Sustainability - minimize environmental impact and incorporate circular practices across operations.
• Collaboration - cross-disciplinary teams and external partnerships to speed innovation.
• Integrity - transparent governance, ethical conduct, and data-driven accountability.

• Accelerate translational research: prioritize pipeline projects with clear clinical or agronomic endpoints and go/no-go gates tied to milestone financing.
• Green manufacturing: retrofit key facilities for energy efficiency, adopt on-site renewables and supplier decarbonization programs to meet the 30% GHG target.
• Customer success programs: implement standardized CSAT and NPS processes, dedicated account teams, and post-market surveillance to lift satisfaction to 95%.
• Internationalization: create legal, regulatory and clinical pathways-establishing EU/NA R&D centers to localize development and speed market entry.
• Human capital investment: roll out structured training curricula, certification programs, and cross-border exchanges to build a high-performance workforce.

• Board-level oversight of sustainability and strategic international expansion to ensure the 2025-2026 targets are monitored and resourced.
• Quarterly KPI reporting integrating environmental metrics, customer satisfaction, and R&D milestones with transparent progress updates.
• Performance-linked budgeting that ties a portion of R&D and operations funding to achievement of the stated KPIs.

Jinyu Bio-technology Co., Ltd. (600201.SS) - Vision Statement

• Innovation-led growth: target R&D intensity of 10-15% of annual revenue to sustain product pipeline expansion and platform diversification.
• Quality and compliance: maintain >99.5% batch release pass rate through ISO/GMP-aligned systems and digital quality controls.
• Sustainability commitments: reduce scope 1 & 2 emissions by 30% and water consumption by 25% within five years through process optimization and renewable energy adoption.
• Customer-centricity: achieve Net Promoter Score (NPS) of +50 in core markets by delivering tailored technical support and fast-response service models.
• Global expansion: establish 3 overseas R&D and application centers and expand exports to 40+ countries within three years.
• Human capital investment: allocate 8%-10% of payroll to training, mentorship, and continuous learning programs annually.

• Research & Development: focus on high-purity biomaterials, peptide chemistry, and enzyme formulation technologies to capture higher-margin specialty segments.
• Manufacturing Excellence: scale modular GMP facilities to enable flexible capacity increases while preserving traceability and product integrity.
• Market Diversification: target medical devices, diagnostics, pharma intermediates, and specialty nutrition markets to reduce single-segment exposure.
• Sustainability & Compliance: integrate green chemistry, waste minimization, and supplier sustainability audits across the value chain.
• Talent & Culture: foster cross-disciplinary teams, performance-based incentives, and global mobility to attract top industry talent.

• Central R&D hub plus two satellite labs: focus areas include peptide synthesis, conjugation chemistry, and novel excipients.
• Pipeline: 18 active projects spanning early-stage formulation to commercial-scale application; goal to advance 4 projects/year into pilot manufacturing.
• Collaborations: strategic partnerships with 6 university and industry consortia to accelerate translational research and licensing opportunities.

• Quality management: integrated QMS with real-time analytics, achieving average batch release time reduction of 22% year-over-year.
• Regulatory milestones: maintain GMP certification across flagship facilities and pursue CE/US FDA registrations for priority products.

• Eco-materials: substitution program targeting 40% of single-use plastics in packaging with biodegradable or recycled alternatives by 2027.
• Process improvements: solvent recovery systems and closed-loop water treatment to lower waste intensity by >20% in two years.

• Tailored solutions: dedicated technical account teams for the top 30 global customers, delivering customized formulations and scale-up support.
• Service KPIs: same-day technical triage for critical queries and average order lead-time target of 10 business days for stocked SKUs.

• Planned international centers: target locations in Europe, North America, and Southeast Asia to localize application development and regulatory support.
• Sales channels: bolster distributor network to cover clinical and industrial customers in emerging markets and OECD countries.

• Training programs: standardized curriculum for GMP, quality assurance, and advanced analytics; >85% employee participation annually.
• Performance metrics: link 30% of variable pay to innovation outcomes, quality KPIs, and sustainability targets.